Meningioma research

The main pathologies treated

Research activities of the Neurosurgery Department

The department has a particular interest in studying the links between meningiomas and exogenous sex hormones.

Our team was the first to demonstrate a causal link between meningiomas and cyproterone acetate (ANDROCUR*), as well as links with other progestins such as normegestrol acetate (LUTENYL*) and Chlormadinone acetate (LUTERAN*).

> To clarify the relationship between drug intake, and in particular the dose and duration of treatment, and the development of meningiomas, a study was carried out by the French Assurance Maladie in cooperation with the neurosurgery department at Lariboisière Hospital.

This study was carried out on 250,000 women exposed to cyproterone, comparing those who received high doses (more than 3g over 6 months, i.e. at least 3 boxes, then continued treatment) with those who received low doses (less than 3g over 6 months, i.e. one or two boxes, then stopped treatment). The occurrence of meningioma in these women was therefore monitored for 7 years.

The results indicate that exposure to high-dose cyproterone acetate exposes women to a 7-fold increased risk of meningioma managed in Neurosurgery, compared with the group of low-exposure women who stopped treatment.

There is also a strong relationship between dose and effect, with the risk increasing more than 20-fold above a cumulative dose of 60 g, i.e. around 5 years’ treatment at 50 mg/d or 10 years’ treatment at 25 mg/d (when taken 20 days a month).

Read more :

Androcur (cyproterone acetate) and generics

Risk of meningioma with prolonged use – Information point

Lutenyl* / Luteran*

Risk of meningioma with prolonged use

AMAVEA Association

Association Cyproterone acetate meningiomas

References:

  • Cyproterone acetate and meningioma: a nationwide population-based study. Champeaux-Depond C, et al. Among authors: froelich s. J Neurooncol. 2021.